Early Oral & Topical Anti-inflammatory Therapies for IBD
Sulfazine / Pharmascience Inc. (1984)
An adjunctive therapy in the treatment of severe ulcerative colitis, proctitis, or distal ulcerative colitis and Crohn’s disease.
Oral
Oral
Treatment of ulcerative colitis, proctitis, and distal colitis.
Oral
Severe attacks: 2–4 500 mg tablets, 3–4 times daily
Moderate and mild attacks:
2 500 mg tablets, 3-4 times daily
Maintenance dose:
2 500 mg tablets, 2–3 times a day
Suggested dosing10:
40 to 70 mg/kg daily up to 4 g daily
*Practice point: also available as a liquid formulation.
CBC and LFTs should be performed at baseline and every second week during the first 3 months of therapy. During the second 3 months, the same tests should be done once monthly and thereafter every 3 months and as clinically indicated.
Renal function should be performed in all patients at baseline and at least monthly for the first 3 months of treatment.
For pediatric population10:
Gradual sulfasalazine dose augmentation over 7 to 14 days may mitigate against dose-dependent side-effects.
5-ASA: 5 -aminosalicylic acid, CBC: complete blood count, LTF: liver function test, eGFR: estimated glomerular filtration rate
For more detailed information regarding side effects, please refer to the appropriate product monograph.
Common Side Effects
• Nausea/Vomiting
• Paradoxical diarrhea
• Allergic hypersensitivity reactions causing rash and mild fever
• Possible decreased sperm count
Serious Side Effects
• Pericarditis
• Allergic interstitial nephritis
• Cytopenia
• Pancreatitis
• Hepatitis
Approved for use in pediatric patients.
According to the product monograph, no special dosage instructions are required for elderly patients.
Should be used with caution in patients with renal disease.
Coming soon
Coming soon
5-ASA: 5- aminosalicylic acid